Vaginal Fungi Infections Treatment Market to Surpass US$ 1,420.1 Million by 2027 - Coherent Market Insights

Global Vaginal Fungi Infections Treatment Market, by Drug Type (Fluconazole, Nystatin, Flucytosine and Others), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Launch of novel products by market players to augment the market growth

Continuous product development and product launches are expected to propel the growth of the market. For instance, in January 2018, Lupin Limited (Lupin) launched Flucytosine capsules USP, 250 mg and 500 mg, which are AB rated generic equivalent of ANCOBON Capsules, 250 mg and 500 mg. Similarly, in November 2017, Perrigo Company plc, launched the generic version of Nystatin and triamcinolone acetonide cream indicated for the treatment of cutaneous candidiasis.

Moreover, major key players in the market are focused on research and development of novel products, which is expected to boost the market growth. For instance, in October 2020, Mycovia Pharmaceuticals, Inc., a late stage emerging biopharmaceutical company, announced that the last patient finished its final visit for the global Phase 3 ‘VIOLET Studies’ for Oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC).

Global Vaginal Fungi Infections Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 30.6 million infected individuals worldwide as of 21^st September 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.

Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as vaginal fungi infections treatment and this is expected to hamper the market growth in the near future.

Browse 37 Market Data Tables and 25 Figures spread through 185 Pages and in-depth TOC on “Vaginal Fungi Infections Treatment Market – by Drug Type (Fluconazole, Nystatin, Flucytosine and Others), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”

To know the latest trends and insights prevalent in the global vaginal fungi infections treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/vaginal-fungi-infections-treatment-market-4271

Key players in the market are focused on strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in July 2020, ANI Pharmaceuticals, Inc. acquired Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company, in order to expand its generic portfolio.

Key Takeaways of the Global Vaginal Fungi Infections Treatment Market:

• The global vaginal fungi infections treatment market is expected to exhibit a CAGR of 5.3% during the forecast period, owing to rising incidence of vaginal fungi infection. For instance, according to an article published in the Current Medical Mycology journal in March 2018, around 50,279 women were diagnosed with vulvovaginal candidiasis (VVC) in Germany from 2014 to 2016.
• Among drug type, fluconazole segment held a dominant position in the vaginal fungi infections treatment market in 2019, owing to its effective indication for the prevention and treatment of a variety of fungal and yeast infections.
• Among route of administration, oral segment held a dominant position in the vaginal fungi infections treatment market in 2019, as market players are focusing on expanding their product portfolio by launching generic versions of antifungal tablets and capsules for the treatment of vaginal fungi infections. This is expected to aid in significant growth of the segment over the forecast period.
• Among distribution channel, hospital pharmacies segment held a dominant position in the vaginal fungi infections treatment market in 2019, as partnerships and agreements of hospitals with specialty pharmacies services providers are expected to drive the segment growth during the forecast period. For instance, in November 2019, Memorial Hospital at Gulfport, Mississippi, entered a partnership with Trellis Rx, to launch a specialty pharmacies services in the hospital.
• Key players operating in the global vaginal fungi infections treatment market include Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.